Restless Legs Syndrome Clinical Trial
Official title:
Yoga vs. Education for Restless Legs Syndrome - a Feasibility Study
Verified date | July 2023 |
Source | West Virginia University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to see whether adults with Restless Legs Syndrome (RLS) are willing to be in a 12-week study where they have a 50-50 chance of being placed in either a gentle yoga program or a film-based education program designed for people with RLS. If so, do they complete the program, and does their RLS, sleep, mood, or quality of life improve?
Status | Completed |
Enrollment | 41 |
Est. completion date | August 15, 2021 |
Est. primary completion date | July 15, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years and older |
Eligibility | Inclusion Criteria: - ambulatory adults - at least 21 years of age - moderate-severe RLS, defined as: 1. symptoms that meet all five of the International RLS Study Group essential diagnostic criteria for RLS (i.e., 1) an urge to move the legs, often associated with discomfort or disagreeable sensations in the legs, that 2) begins or worsen during periods of rest or inactivity; 3) is partially or totally relieved by movement; 4) is worse or only occurs in the evening or night; and 5) is not solely accounted for by another condition (e.g. leg cramps, positional discomfort, habitual foot tapping)); 2. RLS symptoms at least 1x/wk for the previous 3 months; 3. a score of at least 2 points (moderate) IRLS question 6: "How severe was your RLS as a whole?"; and 4. RLS diagnostic criteria applied as per training by the study physician, a sleep medicine expert; these criteria will help ensure exclusion of mimics (e.g. leg cramps, positional discomfort). - willingness and ability to complete the 12-week yoga or educational film program and all study assessments; - willingness to avoid use of any new drugs or treatments other than the assigned intervention. Exclusion Criteria: - practiced yoga within the past year; - currently on dopaminergic agents (eg, ropinirole, pramipexole) or anti-psychotic medication; - changed dosage if any other central nervous system agents (e.g., sedative hypnotics, gamma-aminobutyric acid (GABA) analogs, narcotic analgesics, antiadrenergic agents, or anticonvulsants) within the past 3 months; - any orthopedic, neurologic or other condition that might prevent safe completion of a 12-week yoga program or confound assessments (e.g., neuropathy; Parkinson's disease; stroke; rheumatoid arthritis; renal failure; uncontrolled sleep apnea; recent (within the last 6 months) myocardial infarction; heart failure; cancer (other than non-melanoma skin cancer); - pregnant or within 6 months post-partum). |
Country | Name | City | State |
---|---|---|---|
United States | West Virginia University | Morgantown | West Virginia |
Lead Sponsor | Collaborator |
---|---|
West Virginia University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Recruitment rate | To determine feasibility and acceptability of the programs, we will collect comprehensive information, both overall and by treatment group, on: rates of recruitment and success of different recruitment strategies, and reasons for refusal to participate. | 12 weeks | |
Primary | Retention rates | To determine feasibility and acceptability of the programs, we will collect comprehensive information, both overall and by treatment group, on: rates of retention (completion of assessment visits) | 12 weeks | |
Primary | Adherence rates | To determine feasibility and acceptability of the programs, we will collect comprehensive information, both overall and by treatment group, on rates of adherence (completion of home logs and class attendance rates (yoga and film groups); completion of home practice (yoga group)); | 12 weeks | |
Primary | Participant satisfaction | To determine feasibility and acceptability of the programs, we will collect comprehensive information, both overall and by treatment group, on participant satisfaction, assessed via a structured program evaluation questionnaire regarding participant perceptions of and experiences with the study, and satisfaction regarding their respective programs | 12 weeks | |
Secondary | Yoga dosing preference | A structured questionnaire regarding possible yoga dosing scenarios will be administered at week 12 to determine participant preferences relative to yoga programs of varying duration and intensity (8 weeks, 16 classes (2x/week); 12 weeks, 16 classes (2x/week for the first 4 weeks, once/week thereafter); 16 weeks, 16 classes (once/week), as well as time of year the classes meet. Information from this questionnaire will aid in optimizing the yoga protocol for our future studies. | 12 weeks | |
Secondary | International RLS Rating Scale (IRLS) | To determine effect sizes of the programs, data critical to the design of the planned larger randomized clinical trial. RLS symptom severity, the primary efficacy outcome for the full scale trial, will be evaluated using the IRLS, a 10 item scale which includes questions related to frequency, intensity, and impact. | 12 weeks | |
Secondary | Pittsburgh Sleep Quality Index (PSQI) | Sleep quality will be assessed using the 9-item PSQI | 12 weeks | |
Secondary | Profile of Mood States (POMS) | Mood will be evaluated using the 65-item POMS | 12 weeks | |
Secondary | Perceived Stress Scale (PSS) | 10-item PSS | 12 weeks | |
Secondary | Medical Outcomes Study Short Form-36 (SF-36). | Health-related quality of life will be measured using the 36-item SF-36. | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04786314 -
The Effect of Hot and Cold Water Application on Pregnant Women With Restless Leg Syndrome
|
N/A | |
Completed |
NCT01455012 -
Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome
|
Phase 4 | |
Terminated |
NCT01192503 -
Safety and Efficacy of Rasagiline in Restless Legs Syndrome
|
Phase 2/Phase 3 | |
Completed |
NCT00530530 -
ASP8825 - Study in Patients With Restless Legs Syndrome
|
Phase 2 | |
Completed |
NCT00721279 -
Sifrol (Pramipexole) Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary Restless Legs Syndrome
|
N/A | |
Completed |
NCT00942253 -
Exercise Training in Dialysis Patients With Restless Legs Syndrome (RLS)
|
Phase 2 | |
Completed |
NCT00375284 -
A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS
|
Phase 4 | |
Completed |
NCT00479531 -
Sequential Compression Devices for Treatment of Restless Legs Syndrome
|
Phase 3 | |
Recruiting |
NCT05581576 -
Pitolisant in Refractory Restless Legs Syndrome
|
Phase 4 | |
Active, not recruiting |
NCT03218969 -
Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist
|
Phase 1/Phase 2 | |
Recruiting |
NCT04144790 -
Impact of Iron Supplementation Treatment on Brain Iron Concentrations
|
||
Completed |
NCT05787080 -
Massage, Oxidative and Antioxidant Enzymes in Hemodialysis Patients With Restless Legs Syndrome(RLS)
|
N/A | |
Not yet recruiting |
NCT05529095 -
Sublingual Apomorphine in Refractory Restless Legs Syndrome
|
Phase 4 | |
Recruiting |
NCT05044520 -
Clinical Features Associated With Restless Legs Syndrome.
|
||
Withdrawn |
NCT03849001 -
Impact of Acute Leg Cycling at Various Intensities on RLS Severity in Persons With MS
|
N/A | |
Completed |
NCT03076541 -
Cardiovascular Variability, Heart Rate Response, and Electromyogram Power Associated With Periodic Leg Movements.
|
N/A | |
Recruiting |
NCT04145674 -
A Proof of Concept, Phase 2, Double-blind, Randomized Trial With d-Methadone Product Versus Placebo
|
Phase 2 | |
Completed |
NCT02532608 -
Infra-slow Oscillations During Sleep
|
N/A | |
Completed |
NCT01528462 -
Sleep Disorders Managed and Assessed Rapidly in Transient Ischemic Attack (TIA) and In Early Stroke
|
||
Completed |
NCT00748098 -
Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance
|
Phase 3 |